Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)
China flag China · Delayed Price · Currency is CNY
17.54
+0.21 (1.21%)
At close: Sep 30, 2026

SHE:301246 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
2,3151,9031,7422,0262,0461,568
Other Revenue
83.5936.7828.6928.8717.739.44
2,3991,9391,7712,0552,0641,578
Revenue Growth
36.67%9.53%-13.83%-0.43%30.79%21.10%
Cost of Revenue
1,8641,6151,5901,8141,6221,051
Gross Profit
535.26324.06180.95240.49442.18526.52
Selling, General & Admin
116.07110.2391.3898.5102.96108.41
Research & Development
96.0583.959.1868.8264.0148.71
Other Operating Expenses
12.286.46-5.411.799.4612.27
Operating Expenses
230.81207.41145.67176.55180.73170.42
Operating Income
304.45116.6635.2863.94261.45356.11
Interest Expense
-12.35-13.79-12-13.4-3.41-2.38
Interest & Investment Income
74.0437.6214.1236.47172.05192.11
Currency Exchange Gain (Loss)
-5.46-1.385.631.1113.64-2.62
Other Non Operating Income (Expenses)
0.692.21-1.73-8.43-3.09-1.02
EBT Excluding Unusual Items
361.37141.3141.3179.69440.65542.21
Impairment of Goodwill
------6.5
Gain (Loss) on Sale of Investments
-1.571.853.822.86--
Gain (Loss) on Sale of Assets
-1.670.770.530.5714.44-0.62
Asset Writedown
-18.72-10.81-0.27--1.97-0.76
Other Unusual Items
10.1812.5914.315.4424.8510.72
Pretax Income
349.59145.7259.6998.56477.98545.04
Income Tax Expense
70.0628.098.2311.3943.1851.19
Earnings From Continuing Operations
279.53117.6351.4687.17434.8493.85
Minority Interest in Earnings
1.571.420---
Net Income
281.1119.0551.4787.17434.8493.85
Net Income to Common
281.1119.0551.4787.17434.8493.85
Net Income Growth
2755.27%131.33%-40.96%-79.95%-11.96%92.02%
Shares Outstanding (Basic)
396397399388353353
Shares Outstanding (Diluted)
396397399388353353
Shares Change
-0.40%-0.42%2.71%10.02%-0.00%0.13%
EPS (Basic)
0.710.300.130.221.231.40
EPS (Diluted)
0.710.300.130.221.231.40
EPS Growth
2766.96%132.30%-42.52%-81.78%-11.96%91.78%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-219.59-341.06-176.01-439.39-292.1-62.92
Free Cash Flow Per Share
-0.55-0.86-0.44-1.13-0.83-0.18
Dividend Per Share
0.0500.0500.0300.0500.100-
Dividend Growth
66.67%66.67%-40.00%-50.00%--
Gross Margin
22.31%16.71%10.22%11.70%21.43%33.37%
Operating Margin
12.69%6.02%1.99%3.11%12.67%22.57%
Profit Margin
11.72%6.14%2.91%4.24%21.07%31.30%
Free Cash Flow Margin
-9.15%-17.59%-9.94%-21.38%-14.15%-3.99%
EBITDA
513.24318.14213.02220.09350.53435.77
EBITDA Margin
21.39%16.40%12.03%10.71%16.98%27.62%
D&A For EBITDA
208.78201.48177.74156.1689.0879.66
EBIT
304.45116.6635.2863.94261.45356.11
EBIT Margin
12.69%6.02%1.99%3.11%12.67%22.57%
Effective Tax Rate
20.04%19.27%13.79%11.56%9.03%9.39%
Revenue as Reported
2,3991,9391,7712,0552,0641,578
Advertising Expenses
-1.291.030.80.020.69